Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis

Brain, Behavior, and Immunity

Volumn 22, Issue 3, 2008, Pages 312-317

  Gutiérrez Cañas, Irene ^a   Juarranz, Yasmina ^a   Santiago, Begoña ^b   Martínez, Carmen ^a   Gomariz, Rosa P ^a   Pablos, José Luis ^b   Leceta, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Human; IL 10; PBL; Rheumatoid arthritis; Th1; Th2; Treg; VIP

Indexed keywords

COLLAGEN; INTERLEUKIN 10; INTERLEUKIN 4; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL DIFFERENTIATION; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOREGULATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TH1 CELL;

ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINES; CYTOKINES; HUMANS; IMMUNE SYSTEM; INFLAMMATION MEDIATORS; INTERLEUKIN-10; LYMPHOCYTES; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; UP-REGULATION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 38649114070     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2007.09.007     Document Type: Article

References (26)

1. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
2. + regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 6 (2004) R335-R346
3. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7 (2001) 563-568
4. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Mauri D.A., and Isenberg C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200 (2004) 277-285
5. Firestein G.S. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11 (2005) S39-S44
6. Foey A.D., Field S., Ahmed S., Jain A., Feldmann M., Brennan F.M., and Williams R. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res. Ther. 5 (2003) R317-R328
7. Fournier C. Where do T cells stand in rheumatoid arthritis?. Joint Bone Spine 72 (2005) 527-532
8. Gomariz R.P., Juarranz Y., Abad C., Arranz A., Leceta J., and Martinez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. NY Acad. Sci. 1070 (2006) 51-74
9. + T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 54 (2006) 864-876
10. Gonzalez-Rey E., Varela N., Chorny A., and Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 13 (2007) 1113-1139
11. Gutiérrez-Cañas I., Juarranz Y., Santiago B., Arranz A., Martinez C., Galindo M., Paya M., Gomariz R.P., and Pablos J.L. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology 45 (2006) 527-532
12. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18 (2006) 349-356
13. Hernanz A., Medina S., de Miguel E., and Martín-Mola E. Effect of calcitonin gene-related peptide neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Reg. Peptides 115 (2003) 19-24
14. Juarranz M.G., Santiago B., Torroba M., Gutierrez-Cañas I., Palao G., Galindo M., Abad C., Martinez C., Leceta J., Pablos J.L., and Gomariz R.P. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 43 (2004) 16-22
15. Juarranz Y., Abad C., Martinez C., Arranz A., Gutierrez-Cañas I., Rosignoli F., Gomariz R.P., and Leceta J. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 7 (2005) R1034-R1045
16. Juarranz Y., Gutiérrez-Cañas I., Arranz A., Martinez C., Abad C., Leceta J., Pablos J.L., and Gomariz R.P. VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts. Ann. NY Acad. Sci. 1070 (2006) 359-364
17. Kawashima M., and Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFNγ, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann. Rheum. Dis. 64 (2005) 415-418
18. Kirkham B.W., Lassere M.N., Edmonds J.P., Juhasz M., Bird P.A., Lee C.S., Shnier R., and Portek I.J. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis. Arthritis Rheum. 54 (2006) 1122-1131
19. McInnes I.B., and Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7 (2007) 429-442
20. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17 (1996) 138-146
21. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Immunol. 140 (2005) 360-367
22. Sarkar S., and Fox D.A. Regulatory T cell defects in rheumatoid arthritis. Arthritis Rheum. 56 (2007) 710-713
23. Steiner G., Tohidast-Akrad M., Witzmann G., Vesely M., Studnicka-Benke A., Gal A., Kunaver M., Zenz P., and Smolen J.S. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 38 (1999) 202-213
24. Toh M.L., and Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr. Opin. Rheumatol. 19 (2007) 284-288
25. Van Roon J.A., Lafeber F.P., and Bijlsma J.W. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 44 (2001) 3-12
26. Voice J.K., Grinninger C., Kong Y., Bangale Y., Paul S., and Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170 (2003) 308-314